ASH Letter to FDA re Draft Guidance on Diversity Action Plans for Clinical Studies
Sep 26
2024
Â鶹ÊÓƵ. (2024).
ASH Letter to FDA re Draft Guidance on Diversity Action Plans for Clinical Studies.
Retrieved from /advocacy/policy-news-statements-testimony-and-correspondence/testimony-and-correspondence/ash-letter-to-fda-re-draft-guidance-on-diversity-action-plans-for-clinical-studies.
Â鶹ÊÓƵ.
"ASH Letter to FDA re Draft Guidance on Diversity Action Plans for Clinical Studies." Hematology.org.
/advocacy/policy-news-statements-testimony-and-correspondence/testimony-and-correspondence/ash-letter-to-fda-re-draft-guidance-on-diversity-action-plans-for-clinical-studies
(label-accessed February 20, 2025).
"Â鶹ÊÓƵ."
ASH Letter to FDA re Draft Guidance on Diversity Action Plans for Clinical Studies, 20 Feb. 2025 ,
/advocacy/policy-news-statements-testimony-and-correspondence/testimony-and-correspondence/ash-letter-to-fda-re-draft-guidance-on-diversity-action-plans-for-clinical-studies.
